Aliskiren hemifumarate (CGP 60536; CGP60536B; SPP 100) is an orally active, selective renin inhibitor with an IC50 of 1.5 nM. It is utilized in research pertaining to hypertension, cardiovascular diseases, and cancer cachexia.As a direct renin inhibitor, aliskiren targets the renin-angiotensin-aldosterone system (RAAS), a key pathway in blood pressure regulation. Its role in hypertension management is significant, offering an alternative to traditional antihypertensive medications. Additionally, aliskiren's potential impact on cardiovascular health and cancer cachexia is under investigation, highlighting its broad research applications.